India has earned global recognition for the strength of its pharmaceutical sector, combining scientific talent with manufacturing scale and quality systems that serve both domestic and international health needs. According to the Economic Survey 2025–26, India ranked 11th worldwide in pharmaceutical exports by value, with medicines supplied to 191 countries in FY25. Over the same period, pharmaceutical exports grew significantly, from $1.9 billion in FY01 to $30.5 billion by FY25, demonstrating the sector's scale and growing global footprint.
Yet, the next phase of India's healthcare story cannot be defined by discovery and production alone. The defining leadership question is this: how do we ensure science-led treatments reach patients early, affordably, and consistently across the nation?
The Health Imperative Is Changing Faster Than Access
India's disease burden has shifted decisively toward chronic and complex conditions. Non-communicable diseases such as cardiovascular disease, diabetes, cancer and chronic respiratory illnesses are estimated to account for about 63% of deaths in India; a reminder that healthcare is now as much about long-term management as it is about acute cure. This is evident in everyday life with rising incidence of diabetes in working adults, cardiac events in younger populations, and an increasing need for sustained therapy adherence.
As leaders, we must treat this as both a public health priority and an economic imperative. Chronic diseases erode productivity, household finances, and the resilience of our health system. Innovation must therefore be measured not only in scientific novelty, but in population-level outcomes.
The Scale Vs Inclusion Gap
India has made progress in expanding the healthcare workforce. Government sources estimate the national doctor-population ratio at ~1:811, better than the WHO benchmark of 1:1,000. But the national average masks structural imbalance: doctor availability and infrastructure remain concentrated in urban centres, while rural and tribal districts struggle with distribution, vacancies, and limited secondary/tertiary capacity.
The same inclusion gap shows up in infrastructure. Around 70% of Indians live outside large cities, rural India has a disproportionately smaller share of hospital beds in government facilities, intensifying the "distance to care" problem for time-sensitive conditions. Even where treatment exists, patients often cannot reach it in time or cannot stay connected to it long enough for the treatment to deliver its full benefit. As a result, India does not lack medical progress; it lacks equitable translation of that progress into access.
Affordability Should Be Treated as Core Innovation
For most families, especially those managing chronic disease, the greatest barrier is not whether a medicine exists. It is whether they can afford continuous care. Here, India has made notable strides through financing and accessibility levers that common citizens can relate to.
Under Ayushman Bharat (AB-PMJAY), over 42 crore Ayushman cards had been created as of 2025, and 7.79 crore hospital admissions worth ~Rs 1.5 lakh crore were authorized under the scheme. Similarly, the Pradhan Mantri Bhartiya Janaushadhi Pariyojana expanded access through nearly 17,000 Jan Aushadhi Kendras operational by late 2025, generating an estimated Rs 38,000 crore in savings for citizens compared with branded medicines. These are not only welfare mechanisms; they are structural enablers of adherence. A medicine that is clinically effective but financially inaccessible is, in real-world terms, an incomplete innovation.
The Silent Gaps: Early Diagnosis and Care Continuity
Two persistent challenges continue to limit the impact of science-led treatment in India. The first is delayed diagnosis. Many patients seek care only after the disease has progressed, when therapy becomes more complex, outcomes are harder to improve, and the total cost of care rises. The second challenge is fragmented care journeys. Many patients still move across clinics, diagnostic centres, pharmacies, and hospitals without a connected system to track their medical history or follow-up care. In the absence of coordinated records, reviews are often missed, treatment changes may get delayed, and medication adherence can become inconsistent, ultimately affecting health outcomes.
Addressing these gaps requires innovation to move beyond research, development, and manufacturing and toward connected care design. The focus should be on enabling earlier screening, faster initiation of appropriate treatment, and sustained therapy adherence so that patients can fully benefit from care.
Technology as the Bridge Between Capacity and Reach
Technology is the most practical "force multiplier" available to Indian healthcare because it expands reach without requiring equivalent expansion in physical infrastructure.
The most relatable example is the growth of public telemedicine. eSanjeevani, India's national telemedicine platform, conducted 33.86 crore teleconsultations across 28 states and 8 union territories till 2025. With over 2.3 lakh doctors and health workers, it is a reflection of how quickly virtual care has become mainstream for follow-ups, triage and primary advice.
For a patient in a smaller town, this can mean the difference between delaying care and accessing timely advice. For a district health facility, it can reduce unnecessary referrals and crowding at tertiary centres when integrated effectively into referral pathways.
At the same time, the next frontier lies in the responsible use of data and artificial intelligence across the healthcare value chain. These tools can improve clinical trial design, strengthen pharmacovigilance, and enable smarter supply chains, ensuring more consistent availability of medicines and fewer shortages.
What Needs to Change
For India to move from "innovation at scale" to "innovation with impact," four priorities stand out.
- Design for inclusion by building access pathways that work not only for metros but also for Tier 2/3 India and rural districts.
- Treat affordability as a clinical strategy, recognizing that financing and low-cost availability are essential to improving outcomes in chronic disease.
- Institutionalize early diagnosis so that screening and prevention become routine rather than episodic.
- Connect the care journey by deploying digital health solutions to strengthen continuity across records, follow-ups, adherence, and referral discipline, instead of limiting them to standalone pilots.
The Bottom Line
India's pharmaceutical sector has proved it can compete globally by volume, quality, and increasingly by value. The next challenge is more demanding: making science-led treatment consistently reachable for more people. Ultimately, innovation only matters when it reaches the patient early enough to change the course of disease, affordable enough to sustain adherence, and seamless enough to deliver outcomes. By aligning scientific ambition with inclusive access, India can lead not only as the pharmacy of the world, but also as a model for equitable, science-led healthcare at population scale.
This authored article was first published in ET Pharma on May 13, 2026.
